Therapeutic vaccines against IgE-mediated allergies

References

• Barnes PJ. New therapies for asthma. Trends Mol. Med.12(11), 515–520 (2006).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet368(9537), 780–793 (2006).
   PubMed Web of Science ®Google Scholar
• Belliveau PP. Omalizumab: a monoclonal anti-IgE antibody. Med. Gen. Med.7(1), 27 (2005).
   PubMedGoogle Scholar
• Chang TW, Wu PC, Hsu CL, Hung AF. Anti-IgE antibodies for the treatment of IgE-mediated allergic diseases. Adv. Immunol.93, 63–119 (2007).
   PubMed Web of Science ®Google Scholar
• Nowak D. Management of asthma with anti-immunoglobulin E: a review of clinical trials of omalizumab. Respir. Med.100(11), 1907–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Belliveau PP, Lahoz MR. Evaluation of omalizumab from a health plan perspective. J. Manag. Care Pharm.11(9), 735–745 (2005).
   PubMedGoogle Scholar
• Vernersson M, Ledin A, Johansson J, Hellman L. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J.16(8), 875–877 (2002).
   PubMed Web of Science ®Google Scholar
• Hellman L. Profound reduction in allergen sensitivity following treatment with a novel allergy vaccine. Eur. J. Immunol.24(2), 415–420 (1994).
   PubMed Web of Science ®Google Scholar
• Hellman L. Vaccines against allergies. In: Handbook of Experimental Pharmacology (Volume 133), Vaccines. Perlman P, Wigzell H (Eds). Springer Verlag, Berlin, Germany 499–526 (1999).
   Google Scholar
• Hertz M, Mahalingam S, Dalum I et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol.167(7), 3792–3799 (2001).
   PubMed Web of Science ®Google Scholar
• Ma Y, Hayglass KT, Becker AB et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy62(6), 675–682 (2007).
   PubMed Web of Science ®Google Scholar
• Ma Y, Hayglass KT, Becker AB et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am. J. Respir. Crit. Care Med.176(5), 439–445 (2007).
   PubMed Web of Science ®Google Scholar
• Renard V, Sonderbye L, Ebbehoj K et al. HER-2 DNA and protein vaccines containing potent Th-cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J. Immunol.171(3), 1588–1595 (2003).
   PubMed Web of Science ®Google Scholar
• Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG. Recent advances in contraceptive vaccine development: a mini-review. Hum. Reprod.20(12), 3271–3283 (2005).
   PubMed Web of Science ®Google Scholar
• Talwar GP, Singh O, Pal R et al. A vaccine that prevents pregnancy in women. Proc. Natl Acad. Sci. USA91(18), 8532–8536 (1994).
   PubMed Web of Science ®Google Scholar
• Dalum I, Butler DM, Jensen MR et al. Therapeutic antibodies elicited by immunization against TNF-α. Nat. Biotechnol.17(7), 666–669 (1999).
   PubMed Web of Science ®Google Scholar
• Zagury D, Gallo RC. Anti-cytokine Ab immune therapy: present status and perspectives. Drug Discov. Today9(2), 72–81 (2004).
   PubMed Web of Science ®Google Scholar
• Le Buanec H, Paturance S, Couillin I et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine25(41), 7206–7216 (2007).
   PubMed Web of Science ®Google Scholar
• Garman SC, Wurzburg BA, Tarchevskaya SS, Kinet JP, Jardetzky TS. Structure of the Fc fragment of human IgE bound to its high-affinity receptor, FceRIa. Nature406(6793), 259–266 (2000).
   PubMed Web of Science ®Google Scholar
• Chang TW. The pharmacological basis of anti-IgE therapy. Nat. Biotechnol.18(2), 157–162 (2000).
   PubMed Web of Science ®Google Scholar
• Aveskogh M, Hellman L. Evidence for an early appearance of modern post-switch isotypes in mammalian evolution; cloning of IgE, IgG and IgA from the marsupial Monodelphis domestica. Eur. J. Immunol.28(9), 2738–2750 (1998).
   PubMed Web of Science ®Google Scholar
• Vernersson M, Aveskogh M, Munday B, Hellman L. Evidence for an early appearance of modern post-switch immunoglobulin isotypes in mammalian evolution (II); cloning of IgE, IgG1 and IgG2 from a monotreme, the duck-billed platypus, Ornithorhynchus anatinus. Eur. J. Immunol.32(8), 2145–2155 (2002).
   PubMed Web of Science ®Google Scholar
• Vernersson M, Aveskogh M, Hellman L. Cloning of IgE from the echidna (Tachyglossus aculeatus) and a comparative analysis of epsilon chains from all three extant mammalian lineages. Dev. Comp. Immunol.28(1), 61–75 (2004).
   PubMed Web of Science ®Google Scholar
• Ledin A, Bergvall K, Hillbertz NS et al. Generation of therapeutic antibody responses against IgE in dogs, an animal species with exceptionally high plasma IgE levels. Vaccine24(1), 66–74 (2006).
   PubMed Web of Science ®Google Scholar
• Wagner B, Radbruch A, Rohwer J, Leibold W. Monoclonal anti-equine IgE antibodies with specificity for different epitopes on the immunoglobulin heavy chain of native IgE. Vet. Immunol. Immunopathol.92(1–2), 45–60 (2003).
   PubMed Web of Science ®Google Scholar
• Wan T, Beavil RL, Fabiane SM et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat. Immunol.3(7), 681–686 (2002).
   PubMed Web of Science ®Google Scholar
• Harwood NE, McDonnell JM. The intrinsic flexibility of IgE and its role in binding FcepsilonRI. Biomed. Pharmacother.61(1), 61–67 (2007).
   PubMed Web of Science ®Google Scholar
• Peng C, Davis FM, Sun LK, Liou RS, Kim YW, Chang TW. A new isoform of human membrane-bound IgE. J. Immunol.148(1), 129–136 (1992).
   PubMed Web of Science ®Google Scholar
• Chen HY, Liu FT, Hou CM, Huang JS, Sharma BB, Chang TW. Monoclonal antibodies against the C(e)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells. Int. Arch. Allergy Immunol.128(4), 315–324 (2002).
   PubMed Web of Science ®Google Scholar
• Aveskogh M, Hellman L. A single major transcript encodes the membrane-bound form of rat immunoglobulin E. Scand. J. Immunol.42(5), 535–539 (1995).
   PubMed Web of Science ®Google Scholar
• Hellman L. Characterization of four novel epsilon chain mRNA and a comparative analysis of genes for immunoglobulin E in rodents and man. Eur. J. Immunol.23(1), 159–167 (1993).
   PubMed Web of Science ®Google Scholar
• Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am. J. Respir. Med.2(3), 245–259 (2003).
   PubMedGoogle Scholar
• Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356(9248), 2144–2148 (2000).
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med.167(2), 199–204 (2003).
   PubMed Web of Science ®Google Scholar
• Garrett JK, Jameson SC, Thomson B et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol.113(1), 115–119 (2004).
   PubMed Web of Science ®Google Scholar
• Stein ML, Collins MH, Villanueva JM et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol.118(6), 1312–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Fallon PG, Jolin HE, Smith P et al. IL-4 induces characteristic Th2 responses even in the combined absence of IL-5, IL-9, and IL-13. Immunity17(1), 7–17 (2002).
   PubMed Web of Science ®Google Scholar
• Kruse N, Tony HP, Sebald W. Conversion of human interleukin-4 into a high-affinity antagonist by a single amino acid replacement. EMBO J.11(9), 3237–3244 (1992).
   PubMed Web of Science ®Google Scholar
• Hahn C, Teufel M, Herz U et al. Inhibition of the IL-4/IL-13 receptor system prevents allergic sensitization without affecting established allergy in a mouse model for allergic asthma. J. Allergy Clin. Immunol.111(6), 1361–1369 (2003).
   PubMed Web of Science ®Google Scholar
• Henderson WR Jr, Chi EY, Maliszewski CR. Soluble IL-4 receptor inhibits airway inflammation following allergen challenge in a mouse model of asthma. J. Immunol.164(2), 1086–1095 (2000).
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Corren J et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol.107(6), 963–970 (2001).
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol.130(1), 93–100 (2002).
   PubMed Web of Science ®Google Scholar
• Amin T, Carter G. Immunogenicity issues with therapeutic proteins. Curr. Drug Discov.12, 20–24 (2004).
   Google Scholar
• de Vries JE, Punnonen J, Cocks BG, de Waal Malefyt R, Aversa G. Regulation of the human IgE response by IL-4 and IL-13. Res. Immunol.144(8), 597–601 (1993).
   PubMedGoogle Scholar
• McKenzie GJ, Fallon PG, Emson CL, Grencis RK, McKenzie AN. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J. Exp. Med.189(10), 1565–1572 (1999).
   PubMed Web of Science ®Google Scholar
• Wynn TA. IL-13 effector functions. Annu. Rev. Immunol.21, 425–456 (2003).
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Donaldson DD, Tchistiakova L et al. Efficacy of IL-13 neutralization in a sheep model of experimental asthma. Am. J. Respir. Cell Mol. Biol.36(3), 368–376 (2007).
   PubMed Web of Science ®Google Scholar
• Bree A, Schlerman FJ, Wadanoli M et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J. Allergy Clin. Immunol.119(5), 1251–1257 (2007).
   PubMed Web of Science ®Google Scholar
• Fallon PG, Ballantyne SJ, Mangan NE et al. Identification of an interleukin (IL)-25-dependent cell population that provides IL-4, IL-5, and IL-13 at the onset of helminth expulsion. J. Exp. Med.203(4), 1105–1116 (2006).
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Yoshimoto T, Hayashi N, Mizutani H, Nakanishi K. Induction of allergic inflammation by interleukin-18 in experimental animal models. Immunol. Rev.202, 115–138 (2004).
   PubMed Web of Science ®Google Scholar
• Schmitz J, Owyang A, Oldham E et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity23(5), 479–490 (2005).
   PubMed Web of Science ®Google Scholar
• Brint EK, Xu D, Liu H et al. ST2 is an inhibitor of interleukin 1 receptor and Toll-like receptor 4 signaling and maintains endotoxin tolerance. Nat. Immunol.5(4), 373–379 (2004).
   PubMed Web of Science ®Google Scholar
• Coyle AJ, Lloyd C, Tian J et al. Crucial role of the interleukin 1 receptor family member T1/ST2 in T helper cell type 2-mediated lung mucosal immune responses. J. Exp. Med.190(7), 895–902 (1999).
   PubMed Web of Science ®Google Scholar
• Lohning M, Grogan JL, Coyle AJ et al. T1/ST2 expression is enhanced on CD4+ T cells from schistosome egg-induced granulomas: analysis of Th cell cytokine coexpression ex vivo. J. Immunol.162(7), 3882–3889 (1999).
   PubMed Web of Science ®Google Scholar
• Lohning M, Stroehmann A, Coyle AJ et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc. Natl Acad. Sci. USA95(12), 6930–6935 (1998).
   PubMed Web of Science ®Google Scholar
• Moritz DR, Rodewald HR, Gheyselinck J, Klemenz R. The IL-1 receptor-related T1 antigen is expressed on immature and mature mast cells and on fetal blood mast cell progenitors. J. Immunol.161(9), 4866–4874 (1998).
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Fallon PG, Matthews DJ, Jolin HE, McKenzie AN. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med.191(6), 1069–1076 (2000).
   PubMed Web of Science ®Google Scholar
• Xu D, Chan WL, Leung BP et al. Selective expression of a stable cell surface molecule on type 2 but not type 1 helper T cells. J. Exp. Med.187(5), 787–794 (1998).
   PubMed Web of Science ®Google Scholar
• Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med.203(2), 269–273 (2006).
   PubMed Web of Science ®Google Scholar
• Soumelis V, Reche PA, Kanzler H et al. Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. Nat. Immunol.3(7), 673–680 (2002).
   PubMed Web of Science ®Google Scholar
• Wang YH, Ito T, Wang YH et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity24(6), 827–838 (2006).
   PubMed Web of Science ®Google Scholar
• Yoo J, Omori M, Gyarmati D et al. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J. Exp. Med.202(4), 541–549 (2005).
   PubMed Web of Science ®Google Scholar
• Huston DP, Liu YJ. Thymic stromal lymphopoietin:a potential therapeutic target for allergy and asthma. Curr. Allergy Asthma Rep.6(5), 372–376 (2006).
   PubMed Web of Science ®Google Scholar
• Waterston AM, Gumbrell L, Bratt T et al. Phase I study of TNF-α AutoVaccine in patients with metastatic cancer. Cancer Immunol. Immunother.54(9), 848–857 (2005).
   PubMed Web of Science ®Google Scholar
• van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccination. Trends Immunol.27(1), 49–55 (2006).
   PubMed Web of Science ®Google Scholar
• Klinman DM, Currie D, Gursel I, Verthelyi D. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol. Rev.199, 201–216 (2004).
   PubMed Web of Science ®Google Scholar
• Johansson J, Ledin A, Vernersson M, Lovgren-Bengtsson K, Hellman L. Identification of adjuvants that enhance the therapeutic antibody response to host IgE. Vaccine22(21–22), 2873–2880 (2004).
   PubMed Web of Science ®Google Scholar
• Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B-cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl Acad. Sci. USA,95(16), 9477–9481 (1998).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A. The nucleocapsid of Hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. Science234(4782), 1398–1401 (1986).
   PubMed Web of Science ®Google Scholar
• Milich DR, McLachlan A, Moriarty A, Thornton GB. Immune response to Hepatitis B virus core antigen (HBcAg): localization of T-cell recognition sites within HBcAg/HBeAg. J. Immunol.139(4), 1223–1231 (1987).
   PubMed Web of Science ®Google Scholar
• Lechner F, Jegerlehner A, Tissot AC et al. Virus-like particles as a modular system for novel vaccines. Intervirology45(4–6), 212–217 (2002).
   PubMed Web of Science ®Google Scholar
• Chackerian B, Lenz P, Lowy DR, Schiller JT. Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J. Immunol.169(11), 6120–6126 (2002).
   PubMed Web of Science ®Google Scholar
• Johansson J, Hellman L. Modifications increasing the efficacy of recombinant vaccines; marked increase in antibody titers with moderately repetitive variants of a therapeutic allergy vaccine. Vaccine25(9), 1676–1682 (2007).
   PubMed Web of Science ®Google Scholar
• Hellman L. Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention. Biomed. Pharmacother.61(1), 34–49 (2007).
   PubMed Web of Science ®Google Scholar